OpGen Inc
OTC:OPGN
OpGen Inc
OTC:OPGN
Price:
20
USD
25%
Market Closed
Market Cap:
$204.2m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
OpGen Inc
OTC:OPGN
|
US |
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
JP |
|
F
|
Frontera Group Inc
OTC:FRTG
|
US |
|
A
|
Alfred Herbert (India) Ltd
BSE:505216
|
IN |
|
F
|
Fund.Com Inc
OTC:FNDM
|
US |
|
T
|
Tellhow Sci-Tech Co Ltd
SSE:600590
|
CN |
|
AI Era Corp
OTC:AERA
|
US |
|
D
|
DeFi Development Corp
XMUN:F6S0
|
US |
|
FiEE Inc
NASDAQ:FIEE
|
US |
|
ARYA Sciences Acquisition Corp IV
NASDAQ:ADGM
|
US |
|
M
|
Miami International Holdings Inc
NYSE:MIAX
|
US |
|
Y
|
YAPP Automotive Systems Co Ltd
SSE:603013
|
CN |
|
M
|
Miji International Holdings Ltd
HKEX:1715
|
CN |
|
G
|
Gerdau SA
BOVESPA:GGBR3
|
BR |
|
Q
|
Qualcomm Inc
XETRA:QCI
|
US |
|
SJW Group
NASDAQ:HTO
|
US |
Multiples-Based Value
The Multiples-Based Value of one
OPGN
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 20 USD,
OpGen Inc
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
OPGN Multiples-Based Value
LOCKED
Multiples Across Competitors
OPGN Competitors Multiples
OpGen Inc Competitors
OpGen Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
OpGen Inc
OTC:OPGN
|
241.7m USD | 26.9 | 15.5 | 35.9 | 36.9 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
369.2B USD | 6 | 88.2 | 14.6 | 20.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
187.5B USD | 5.1 | 24.3 | 14.1 | 14.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
173.4B USD | 5.9 | 20.4 | 12.7 | 15.7 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
111.4B USD | 9.3 | 28.2 | 21.2 | 22.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.5B USD | 5.6 | 17.9 | 13.3 | 15.2 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67B AUD | 3.1 | 34 | 11.3 | 14.2 | |
| NL |
|
argenx SE
XBRU:ARGX
|
39.6B EUR | 11.3 | 36.2 | 39.3 | 40.1 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
